Apis Capital Advisors LLC Acquires 86,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX

Apis Capital Advisors LLC lifted its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 13.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 724,000 shares of the company’s stock after purchasing an additional 86,000 shares during the period. Syndax Pharmaceuticals accounts for about 2.7% of Apis Capital Advisors LLC’s portfolio, making the stock its 15th largest position. Apis Capital Advisors LLC’s holdings in Syndax Pharmaceuticals were worth $15,211,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Palumbo Wealth Management LLC bought a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth $1,079,000. Torray Investment Partners LLC bought a new position in Syndax Pharmaceuticals in the fourth quarter valued at about $2,055,000. SG Americas Securities LLC boosted its holdings in Syndax Pharmaceuticals by 184.5% in the fourth quarter. SG Americas Securities LLC now owns 129,227 shares of the company’s stock valued at $2,715,000 after acquiring an additional 83,801 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Syndax Pharmaceuticals by 2.1% in the third quarter. Vanguard Group Inc. now owns 5,138,617 shares of the company’s stock valued at $79,058,000 after acquiring an additional 104,683 shares during the last quarter. Finally, Aberdeen Group plc boosted its holdings in Syndax Pharmaceuticals by 22.9% in the third quarter. Aberdeen Group plc now owns 372,792 shares of the company’s stock valued at $5,735,000 after acquiring an additional 69,366 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SNDX shares. Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price target (down from $48.00) on shares of Syndax Pharmaceuticals in a report on Monday, March 30th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Syndax Pharmaceuticals in a report on Friday, June 12th. Stifel Nicolaus set a $45.00 price target on Syndax Pharmaceuticals in a report on Friday, February 27th. Mizuho decreased their price target on Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating on the stock in a report on Tuesday, March 31st. Finally, JPMorgan Chase & Co. raised their price target on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the company an “overweight” rating in a report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.55.

Syndax Pharmaceuticals Trading Up 2.6%

NASDAQ:SNDX opened at $19.04 on Thursday. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.59 and a 1-year high of $25.59. The business’s 50-day moving average price is $20.68 and its two-hundred day moving average price is $21.21. The company has a current ratio of 5.47, a quick ratio of 5.06 and a debt-to-equity ratio of 8.26. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -6.82 and a beta of 0.38.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Thursday, April 30th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative return on equity of 256.65% and a negative net margin of 111.88%.The firm had revenue of $64.86 million for the quarter, compared to analyst estimates of $69.76 million. During the same quarter in the prior year, the firm posted ($0.98) earnings per share. The company’s quarterly revenue was up 224.3% on a year-over-year basis. On average, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -1.66 earnings per share for the current year.

Insider Transactions at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 6,847 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $18.99, for a total transaction of $130,024.53. Following the sale, the chief executive officer owned 484,843 shares of the company’s stock, valued at $9,207,168.57. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CMO Nicholas A.J. Botwood sold 31,235 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $18.14, for a total value of $566,602.90. Following the sale, the chief marketing officer directly owned 60,885 shares in the company, valued at approximately $1,104,453.90. This represents a 33.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 73,539 shares of company stock worth $1,336,019. 4.80% of the stock is currently owned by insiders.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.